Takeda Pharmaceutical Company Limited Am (NYSE:TAK)

Healthcare

Takeda Pharmaceutical Company is engaged in the research, production, development, and commercialization of biopharmaceutical products.

The company’s history dates back to 1781, when founder Chobei Takeda started selling traditional herbal medicines in Osaka. However, it was officially incorporated in 1925 as Chobei Takeda & Co Ltd, with its headquarters in Tokyo, Japan.

The company’s signature products include:
• TAKECAB
• ENTYVIO
• GATTEX
• ALOFISEL
• NATPAR
• ELAPRASE
• VPRIV
• CUVITRU
• NINLARO
• ALUNBRIG
It is also engaged in manufacturing, sales and marketing, export and import of pharmaceutical drugs.

The company operates research and development facilities in Tokyo, Osaka, Shonan and Hikari, while the production facilities are situated in the regions of Osaka and Hikari.

The Japan-based company also operates through various regional offices in Mexico, China, the Middle East, South America, and Asia-Pacific.

It focuses on four core therapeutic areas such as:
• Gastroenterology
• Oncology
• Neuroscience
• Rare genetics
• Hematology
• Plasma-derived therapies
• Vaccines

In May 2021, the Japanese firm announced the results of its dengue vaccine candidate, TAK-003. The company claims under the long-term analysis, TAK-003, showed continued protection against hospitalization and dengue illness.

It also mentioned no important safety risks were detected regardless of a patient’s exposure to dengue in the ongoing clinical trial, TIDES, the company claims. The pharmaceutical company further added that as many as 20,000 healthy children and adolescents between the 14 to 16 age group were enrolled under the study in Latin America and Asia.

The Japanese pharmaceutical firm operates through various subsidiaries, including Takeda France S.A.S, Takeda Oncology, Baxter AG, Takeda Canada, Inc, TAP Pharmaceuticals, Takeda UK Limited, Millennium Pharmaceutical Inc, Takeda Pharma A/S and Takeda GmbH.

Its ADRs are listed for trading on the New York Stock Exchange (NYSE) under the quote of ‘TAK’. American Depository Receipts is a certificate that represents shares in foreign stocks and are denominated in US dollars. It is a liquid way for the investors based in the United States to trade in stocks of foreign companies.

Contact Information

company address Costa Saroukos 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668, Japan

company phone81 3 3278-2306

company email[email protected]

company websitewww.takeda.com

Similar Companies

Load More